Waldencast plc (NASDAQ:WALD - Get Free Report) shares hit a new 52-week low on Wednesday . The stock traded as low as $4.71 and last traded at $4.71, with a volume of 11555 shares. The stock had previously closed at $4.89.
Analyst Ratings Changes
Separately, Telsey Advisory Group decreased their price target on Waldencast from $10.00 to $8.00 and set an "outperform" rating on the stock in a research note on Wednesday, May 1st.
Read Our Latest Report on WALD
Waldencast Price Performance
The firm's fifty day simple moving average is $6.22 and its 200-day simple moving average is $8.02.
Institutional Trading of Waldencast
Large investors have recently made changes to their positions in the stock. Zeno Equity Partners LLP acquired a new stake in shares of Waldencast during the fourth quarter worth $224,278,000. Truxt Investmentos Ltda. grew its holdings in Waldencast by 3.7% in the 4th quarter. Truxt Investmentos Ltda. now owns 4,075,479 shares of the company's stock valued at $44,586,000 after buying an additional 144,841 shares during the period. Bank of New York Mellon Corp grew its holdings in Waldencast by 73.6% in the 3rd quarter. Bank of New York Mellon Corp now owns 86,409 shares of the company's stock valued at $814,000 after buying an additional 36,642 shares during the period. Simplicity Wealth LLC acquired a new position in shares of Waldencast during the 1st quarter valued at about $142,000. Finally, Bleakley Financial Group LLC purchased a new position in shares of Waldencast during the 1st quarter worth about $142,000. Institutional investors and hedge funds own 41.97% of the company's stock.
About Waldencast
(
Get Free Report)
Waldencast plc operates in the beauty and wellness business. The company engages in developing, acquiring, accelerating, and scaling various brands. It provides cosmetic, over-the-counter, and prescription products under the Obagi Medical, Obagi Clinical, and Obagi Professional brands; and a Skintrinsiq device for use in facial treatments that is used by physicians' offices, spas, and aestheticians.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Waldencast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Waldencast wasn't on the list.
While Waldencast currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
